OCT IMAGING OF SUB-SCLERAL CHANNELS CREATED WITH FEMTOSECOND

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 飞秒激光可以通过透明和半透明的组织进行高精度的外科手术，而不会损伤表面或邻近的组织。飞秒激光与组织相互作用的这些独特特性为青光眼的传统激光治疗提供了相当大的潜在优势。青光眼是导致失明的主要原因之一，仅在美国就有超过200万人患有青光眼。这种情况的特点是眼压增加，导致眼底细胞逐渐永久性死亡，导致失明。青光眼的治疗重点是通过减少眼内维持眼压的液体的产生或增加眼内液体的排出来降低眼压。 目前，传统的治疗方法包括使用眼药水、激光或手术，但这些治疗方法的使用可能会很麻烦，并会造成许多并发症，如疤痕形成，尤其是手术后。我们推测飞秒激光的应用可能用于青光眼的治疗。在与传统青光眼治疗方法相比的几个潜在优势中，最重要的是它能够为房水流出创造引流通道，而不会对覆盖或邻近的组织造成附带损害。这可能会增加引流通道的寿命，使其能够将眼压保持在正常范围内。 为了验证我们的假设，我们提出了对飞秒激光技术在活体动物模型中创建引流通道的评估。同一研究小组已经在另一个实验室(密歇根大学)建立了一个房水流出的体外模型，作为了解飞秒激光创建的引流通道对身体眼睛房水流出的影响的第一步。从身体眼实验中获得了该通道的最佳形状和深度。 在体外研究之后，有必要确定飞秒激光技术在活体动物模型上建立引流通道的效果。此外，引流通道降低眼内压的效果也可以在体内进行评估。 目标： 1.利用活体动物模型和标准房水流出量测量技术，验证了飞秒激光治疗青光眼的有效性，并优化了治疗程序 2.通过使用活体动物模型进行伤口愈合研究，研究飞秒激光产生的流出通道的寿命和通畅性 在另一个位置进行全身麻醉后，每只兔子将被运送到BLI进行OCT眼部成像，然后返回调查人员的实验室进行康复。 所有动物研究将在UCI IACUC批准的动物协议#2005-2567下进行，并且该协议的副本、IACUC批准和对协议的任何批准的修改将提供给BLI。Tibor Juhasz博士(Ph：949-824-8769)将被指定为BLI动物程序的监督方。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Femtosecond lasers can be delivered through transparent and translucent tissue to perform high precision surgical procedures without damage to the superficial or adjacent tissues. These unique properties of the femtosecond laser-tissue interactions provides considerable potential advantage over traditional laser treatments used for glaucoma. Glaucoma is one of the leading causes of blindness with over 2 million people affected in the US alone. The condition is characterized by increased pressure in the eye which causes gradual, permanent cell death in the fundus resulting in blindness. Treatment of glaucoma focuses on lowering the eye pressure by reducing the production of fluid in the eye that maintains the pressure (aqueous) or increasing the drainage of this fluid out of the eye. At present, the traditional treatment would include use of eye drops, laser, or surgery however, use of these treatments may be cumbersome and poses a lot of complications such as scar formation especially after surgery. We hypothesize that the application of the femtosecond laser may be used to treat glaucoma. Among several potential advantages over the traditional glaucoma treatments the most important is its ability to create drainage channels for aqueous outflow without collateral damage to the overlying or adjacent tissue. This will likely increase the longevity of the drainage channel that can maintain eye pressure within normal range. To test our hypothesis, we propose the evaluation of femtosecond laser technology for the creation of drainage channels in an in vivo animal model. An in-vitro model of the aqueous outflow was already created by the same group in another laboratory (University of Michigan) as an initial step to understand the effect of femtosecond laser created drainage channels on the aqueous outflow in cadaver eyes. The best shape and depth of the channel was obtained from this cadaver eye experiment. After the in-vitro study, it is necessary to establish the efficacy of the femtosecond laser technology for the creation of drainage channels in a live animal model. Additionally, the efficacy of the drainage channels for decreassing intraoccular pressure can also evaluated in vivo. Aims: 1. Demonstrate the efficacy of femtosecond laser glaucoma treatment and optimize the procedure using in vivo animal models and standard measurement techniques of the aqueous outflow 2. Investigate longevity and patency of femtosecond laser-created outflow channels by performing wound-healing studies using in vivo animal models Following general anesthesia at another location, each rabbit will be transported to BLI for OCT imaging of its eyes and then returned to the investigator's lab for recovery. All animal studies will be performed under and in accordance with the UCI IACUC approved animal protocol #2005-2567, and that a copy of that protocol, the IACUC approval and any approved modifications of the protocol will be provided to BLI. Tibor Juhasz, PhD (Ph: 949-824-8769) will be designated as the responsible party for oversight of the animal procedures at BLI.